|Bid||40.24 x 800|
|Ask||40.24 x 900|
|Day's range||39.09 - 48.34|
|52-week range||22.92 - 111.36|
|Beta (3Y monthly)||3.02|
|PE ratio (TTM)||7.62|
|Earnings date||5 Nov 2018 - 9 Nov 2018|
|Forward dividend & yield||N/A (N/A)|
|1y target est||89.38|
Wall Street analysts anticipate that Acadia Pharmaceuticals (ACAD) will report net income of -$63.01 million for the third quarter of 2018. It was -$63.3 million in the second quarter, which compares to -$67.4 million in the second quarter of 2017. In the first half of this year, its net income was -$117.66 million. In the first half of 2017, it was -$155.3 million.
In October, ten analysts are covering Nektar Therapeutics (NKTR) stock. Eight of them have given the stock a “buy” or higher rating, and two have given it a “hold.” The mean rating for the stock is 1.8 with a target price of $89.38, implying an upside potential of 82.1% over its closing price of $49.08 on October 15.
Nektar Therapeutics’ (NKTR) cost of goods sold was $5.52 million in the second quarter of 2018 compared to $8.99 million in the second quarter of 2017.
Nektar Therapeutics (NKTR) is focused on developing a strong pipeline of product candidates that utilize its polymer conjugate technology platforms. Its research pipeline includes investigational drugs for cancer, autoimmune diseases, and chronic pain. Nektar Therapeutics generated revenues of $1.09 billion in the second quarter of 2018.
Pomerantz LLP is investigating claims on behalf of investors of Nektar Therapeutics (“NKTR” or the “Company”) (NASDAQ: NKTR). Such investors are advised to contact Robert S. Willoughby at firstname.lastname@example.org or 888-476-6529, ext. Following publication of the Plainview report, Nektar’s stock price fell $5.63 per share, or 9.24%, over the following two trading sessions, closing at $55.33 per share on October 2, 2018.
In September 2018, the US FDA granted Portola Pharmaceuticals’ cerdulatinib, an investigational Syk/JAK inhibitor, an orphan drug designation for peripheral T-cell lymphoma (or PTCL) therapy. The FDA grants this designation to support the development of therapies for rare diseases. This designation provides benefits such as seven years of market exclusivity after approval, tax credits for certain clinical trials, and exemption of FDA application fees.
Jim Cramer shares his take on callers' favorite stocks at lightning speed, including a defense play that he got flak for recommending.
Holzer & Holzer, LLC is investigating whether Nektar Therapeutics complied with the federal securities laws. On October 1, 2018, Plainview LLC published a report raising questions about Nektar’s claims concerning its clinical stage drug, NKTR-214, and its ability to effectively treat cancer.
Here's what you need to know about a report that suggests Bristol invested $1.85 billion into a program worth absolutely nothing.
The Zacks Analyst Blog Highlights: Champions Oncology, CytoDyn, Infinity Pharmaceuticals, Nektar Therapeutics and Zoetis
BioXcel Therapeutics, Inc. (“BTI”) (BTAI), a clinical stage biopharmaceutical development company utilizing novel artificial intelligence approaches to identify the next wave of medicines across neuroscience and immuno-oncology, and Nektar Therapeutics (NKTR) announced today that the companies are expanding their ongoing research collaboration into a new clinical partnership.
In the second quarter, Spectrum Pharmaceuticals (SPPI) generated net revenues of $24.2 million compared to $34.3 million in Q2 2017. In the first half of the year, Spectrum Pharmaceuticals reported net revenues of $54.7 million compared to $63.4 million in H1 2017.
On September 6, Spectrum Pharmaceuticals stock closed at $22.25, which is a ~5.70% rise from its close of $21.05 on September 5, 2018. On September 6, Spectrum Pharmaceuticals stock price closed at $22.25, which represents ~146% growth from its 52-week low of $9.03 on September 22, 2017. Spectrum Pharmaceuticals hit its 52-week high of $25.29 on August 27, 2018.
NEW YORK, Aug. 31, 2018-- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Caesars ...
Under its immunology program, Nektar Therapeutics (NKTR) is developing NKTR-358 in collaboration with Eli Lilly and Company (LLY).
In July, Nektar Therapeutics’ (NKTR) new drug application for NKTR-181 was accepted for filing by the FDA. A first-in-class analgesic, NKTR-181 is targeted at the treatment of chronic low back pain in adult patients who are new to opioid therapy.
How Is Nektar Therapeutics Positioned in August? In February, Nektar Therapeutics (NKTR) and Bristol-Myers Squibb (BMY) entered into a collaboration to jointly develop the former’s NKTR-214 in combination with the latter’s Opdivo and Opdivo plus Yervoy and other compounds. The two companies also agreed that Nektar would retain the right to record all global sales of the drug.
How Is Nektar Therapeutics Positioned in August? Nektar Therapeutics expects an increase in its general and administrative expenses in 2018 compared to 2017 due to higher noncash stock-based compensation expenses. Nektar Therapeutics saw an operating income of -$50.66 million in the second quarter of 2017 compared to its operating income of $973.6 million in the second quarter of 2018.
Nektar Therapeutics (NKTR), a research-focused biopharmaceutical company, is developing a strong pipeline of product candidates that make use of its polymer conjugate technology platforms. This pipeline includes investigational drugs for the treatment of cancer, autoimmune disease, and chronic pain.
Nektar Therapeutics (NKTR) generated revenue of $1.09 billion in the second quarter compared to $34.59 million in the second quarter of 2017.